Year:  2017 2018 2019 2020 2021 2022 2023 2024 2025 

QPP Measure #506

Positive PD-L1 Biomarker Expression Test Result Prior to First-Line Immune Checkpoint Inhibitor Therapy

Percentage of patients, aged 18 years and older, with a diagnosis of metastatic non-small cell lung cancer (NSCLC) or squamous cell carcinoma of head and neck (HNSCC) on first-line immune checkpoint inhibitor (ICI) therapy, who had a positive PD-L1 biomarker expression test result prior to giving ICI therapy.

Submission Methods: Registry
Measure Sets: Oncology

The following codes apply for this QPP measure:

HCPCS Codes

CodeDescription
M0001Advancing cancer care mips value pathways
demo
request yours today
subscribe
start today
newsletter
free subscription

Thank you for choosing Find-A-Code, please Sign In to remove ads.